AI-Driven Genomics
for Pharma
We Deliver Profound Insight into the
Genetic Drivers of Disease
Genomenon and Ultragenyx in Human Mutation
Read the latest rare disease publication about our work with Ultragenyx Pharmaceutical
Pharma companies need comprehensive genomic information to drive successful precision medicine programs, but decisions are often made using only a fraction of the data available…about 10%.
Genomenon delivers 100% of the data.
LATEST WEBINAR WITH INOZYME PHARMA
Locus-Specific Patient Databases for Rare Disease:
A Computational Approach
Patient Landscapes Enrich Natural History Studies
An efficient and cost-effective natural history research solution for Pharma, ProdigyTM Patient Landscapes support the development of rare disease therapies by enhancing insights contained in retrospective and prospective health data. Using a powerful AI-driven approach, Genomenon delivers comprehensive and expert assessment of every patient in the published medical literature – in a fraction of the time.
READ MORE
ARTICLE | Comprehensive Genomic Landscape for ALS
Read the latest article in the Journal of Precision Medicine revealing the clinical and genetic complexity of ALS.
5X More Variants in Weeks
Genomenon identified all of the genomic drivers in TARDBP associated with ALS in just two weeks…a yield of 435% more than the number of disease-causing variants found in ClinVar
Comprehensive
Don’t miss anything – get insight into every genomic biomarker published in the medical literature
Evidence-Based
Every scientific assertion is supported by empirical evidence from the medical literature
NEW REPORT: Key Findings from the Genomic Landscape for ALS Discover profound insights from Genomenon’s comprehensive ProdigyTM Genomic Landscape for ALS, and their impact on Pharma
De-Risk Your Precision Medicine Program
UNCOVER
3-10X MORE TARGETS
Identify all genetic drivers and pinpoint which variants are known to be pathogenic according to ACMG clinical standards
GAIN INSIGHT
INTO DISEASE MECHANISM
Better understand the role of pathogenic variants and their functional consequence on disease presentation, backed by evidence
IDENTIFY
MORE OF THE RIGHT PATIENTS
Identify all genetic drivers and pinpoint which variants are known to be pathogenic according to ACMG clinical standards
DE-RISK
CLINICAL TRIAL OUTCOMES
De-risk your precision medicine program by applying the genetic knowledge gained by working with Genomenon
Learn how a leading rare disease pharma company leveraged genomics to target their clinical trials.
ProdigyTM Genomic Landscapes provide the complete picture of a disease or pathway with a unique 2-pronged approach
AI-Driven
Genomenon’s Computational Intelligence organizes and indexes all medical evidence and makes it easily searchable
Expertly Curated
Genomenon’s Experts assess the variants for clinical effect, score for pathogenicity, and review to ensure data quality
ALS GENOMIC LANDSCAPE NOW AVAILABLE!
Genomenon’s comprehensive and organized collection of genomic evidence significantly accelerated our work in several key steps along our development process.
Genomenon’s methodology improved the efficiency and completeness of our literature review process.